2023 World Conference on Lung Cancer (Posters)-EP03.03. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS CoV2 Vaccination in Patients with Non Small Cell Lung Cancer

EP03.03. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS CoV2 Vaccination in Patients with Non Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to explore the impact of tyrosine kinase inhibitors (TKIs) on the immune response to SARS-CoV-2 vaccination in patients with non-small cell lung cancer (NSCLC). The researchers collected blood samples from 92 NSCLC patients and 27 healthy individuals after they received a COVID-19 vaccine. They measured SARS-CoV-2 antibodies using a serum surrogate virus neutralization test kit and analyzed B-cell subsets using flow cytometry. The participants in the healthy cohort received different vaccines, with AZD1222 being the most common, while NSCLC patients predominantly received AZD1222, BNT162b2, and CoronaVac. Healthy individuals showed a higher production of neutralizing antibodies against SARS-CoV-2 compared to NSCLC patients. Among NSCLC patients, those undergoing chemotherapy or TKIs developed antibodies in 42.1% and 58.9% of cases, respectively. Patients receiving TKIs had higher median antibody production compared to those on chemotherapy. Immunotherapy-treated patients did not develop antibodies after vaccination. A sub-analysis comparing EGFR and ALK alterations showed that patients with ALK alterations had higher antibody titers and B-cell quantification against the spike protein of the SARS-CoV-2 virus compared to those with EGFR mutations. The study suggests that TKIs may impair antibody production and B-cell activity in NSCLC patients with EGFR mutations. Overall, the findings indicate that the immune response to SARS-CoV-2 vaccination could be influenced by the type of oncologic treatment received and the specific genetic mutations present in NSCLC patients.

Asset Subtitle

Norma Hernández Pedro

Meta Tag

Speaker Norma Hernández Pedro

Topic Tumor Biology: Translational Biology - IO

Keywords

tyrosine kinase inhibitors

immune response

SARS-CoV-2 vaccination

non-small cell lung cancer

NSCLC

COVID-19 vaccine

SARS-CoV-2 antibodies

B-cell subsets

chemotherapy

immunotherapy